ESR1 and breast cancer: As the molecular subtypes differ in terms of relapse free survival and overall survival [ER negative HER2 negative and HER2 positive breast cancer patients experience a shorter relapse free survival and overall survival] and the nodal status is the strongest prognostic predictor, we highlighted a very complex interaction network between the primary tumour, the nodal status and the distant metastases.